HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments.
HER2-positive
metastatic breast cancer
targeted therapies
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Mar 2023
13 Mar 2023
Historique:
received:
19
02
2023
revised:
07
03
2023
accepted:
11
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
For several years, the overexpression of the HER2 receptor in breast cancer has been correlated with a poor prognosis and an increased risk of developing brain metastases. Currently, the combination of anti-HER2 double blockade and taxane and trastuzumab emtansine (T-DM1) are considered the standard treatments for metastatic breast cancer overexpressing these receptors in the first and second line. Very recently, the development of a new antidrug conjugate, trastuzumab-deruxtecan, has improved the overall survival of patients, even in second-line treatment. However, trastuzumab-deruxtecan has become a new standard. Despite the benefits of these antidrug conjugates, this benefit in patients with brain metastases remains unclear. Tucatinib is a new tyrosine kinase inhibitor that has given hope for the treatment of these patients. The objective of this article was to review data on the established drugs and novel agents for HER2-positive MBC and to discuss how to incorporate anti-HER2 therapies in first and later-line settings.
Identifiants
pubmed: 36980624
pii: cancers15061738
doi: 10.3390/cancers15061738
pmc: PMC10046228
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Clin Oncol. 2017 Sep 10;35(26):3030-3038
pubmed: 28437161
J Clin Oncol. 2021 Jan 1;39(1):79-89
pubmed: 32822287
Lancet Oncol. 2014 May;15(6):580-91
pubmed: 24742739
Oncology (Williston Park). 2002 Oct;16(10):1340-8, 1351-2; discussion 1352, 1355-8
pubmed: 12435204
Lancet Oncol. 2020 Oct;21(10):1283-1295
pubmed: 33002436
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Clin Breast Cancer. 2011 Apr;11(2):103-13
pubmed: 21569996
Lancet Oncol. 2019 Mar;20(3):371-382
pubmed: 30765258
Breast Cancer Res. 2014 Sep 11;16(5):430
pubmed: 25212826
Lancet. 2023 Jan 14;401(10371):105-117
pubmed: 36495879
Cancer Res. 2007 Sep 15;67(18):8882-90
pubmed: 17875730
J Clin Oncol. 2012 Jul 20;30(21):2585-92
pubmed: 22689807
Mol Cancer Ther. 2015 Apr;14(4):952-63
pubmed: 25646013
J Clin Oncol. 2009 Apr 20;27(12):1999-2006
pubmed: 19289619
J Clin Oncol. 2010 Mar 1;28(7):1124-30
pubmed: 20124187
Front Oncol. 2022 Jun 17;12:899782
pubmed: 35785172
Ann Oncol. 2017 Feb 1;28(2):305-312
pubmed: 27998961
Lancet Oncol. 2017 Nov;18(11):1512-1522
pubmed: 29037983
Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242
pubmed: 24919460
Breast Cancer Res Treat. 2011 Jul;128(2):347-56
pubmed: 20730488
Mol Cancer Ther. 2015 Mar;14(3):692-703
pubmed: 25589493
Pathobiology. 2022;89(5):278-296
pubmed: 35500561
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
J Clin Oncol. 2018 Oct 1;36(28):2826-2835
pubmed: 30106636
Ann Oncol. 2019 May 1;30(5):766-773
pubmed: 30796821
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
J Clin Oncol. 2017 Jan 10;35(2):141-148
pubmed: 28056202
J Clin Oncol. 2008 Apr 10;26(11):1789-96
pubmed: 18347005
Lancet Oncol. 2017 Jan;18(1):52-62
pubmed: 27964843
Arch Pathol Lab Med. 2014 Feb;138(2):241-56
pubmed: 24099077
Breast Cancer Res Treat. 2010 Jan;119(1):127-36
pubmed: 19690954
Breast Cancer Res. 2016 Dec 13;18(1):126
pubmed: 27955684
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
J Clin Oncol. 2005 Jul 1;23(19):4265-74
pubmed: 15911866
Arch Pathol Lab Med. 2014 Feb;138(2):213-9
pubmed: 24164555
Cancer Res. 2004 Jun 1;64(11):3958-65
pubmed: 15173008
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
JAMA Oncol. 2016 Jan;2(1):56-64
pubmed: 26469139
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Breast Cancer Res Treat. 2008 Dec;112(3):533-43
pubmed: 18188694
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Lancet Oncol. 2020 Jun;21(6):763-775
pubmed: 32353342
Oncologist. 2010;15(9):924-34
pubmed: 20736298
Clin Breast Cancer. 2020 Apr;20(2):e181-e187
pubmed: 31735691
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Bull Cancer. 2021 Dec;108(11S):11S19-11S25
pubmed: 34969512
Lancet Oncol. 2019 Jun;20(6):816-826
pubmed: 31047803
Ann Oncol. 2012 Jun;23(6):1436-41
pubmed: 22039084
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
JAMA Oncol. 2017 Mar 01;3(3):335-341
pubmed: 27812689
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
JAMA Oncol. 2016 Dec 01;2(12):1557-1564
pubmed: 27078022
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2008 May 1;14(9):2710-6
pubmed: 18451236
Clin Cancer Res. 2017 Jul 15;23(14):3529-3536
pubmed: 28053022
Nat Rev Drug Discov. 2014 Feb;13(2):140-56
pubmed: 24481312
Breast Cancer Res. 2014 Mar 05;16(2):209
pubmed: 24887180
Expert Opin Biol Ther. 2021 Feb;21(2):127-133
pubmed: 33238772
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716